Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma.
Ortiz-Ruiz A, Ruiz-Heredia Y, Morales ML, Aguilar-Garrido P, García-Ortiz A, Valeri A, Bárcena C, García-Martin RM, Garrido V, Moreno L, Gimenez A, Navarro-Aguadero MÁ, Velasco-Estevez M, Lospitao E, Cedena MT, Barrio S, Martínez-López J, Linares M, Gallardo M. Ortiz-Ruiz A, et al. Among authors: cedena mt. Cancers (Basel). 2021 Apr 1;13(7):1662. doi: 10.3390/cancers13071662. Cancers (Basel). 2021. PMID: 33916196 Free PMC article.
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
Alonso R, Cedena MT, Gómez-Grande A, Ríos R, Moraleda JM, Cabañas V, Moreno MJ, López-Jiménez J, Martín F, Sanz A, Valeri A, Jiménez A, Sánchez R, Lahuerta JJ, Martínez-López J. Alonso R, et al. Among authors: cedena mt. Am J Hematol. 2019 Aug;94(8):853-861. doi: 10.1002/ajh.25507. Epub 2019 Jun 9. Am J Hematol. 2019. PMID: 31074033 Free article.
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Alonso R, et al. Among authors: cedena mt. Blood Adv. 2020 May 26;4(10):2163-2171. doi: 10.1182/bloodadvances.2020001508. Blood Adv. 2020. PMID: 32433744 Free PMC article.
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. Cedena MT, et al. PLoS One. 2020 Aug 31;15(8):e0237155. doi: 10.1371/journal.pone.0237155. eCollection 2020. PLoS One. 2020. PMID: 32866200 Free PMC article.
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete ME, Garcia-Alvarez M, Prieto-Conde I, Chillon C, Alcoceba M, Gutierrez NC, Oriol A, Rosinol L, Bladè J, Gironella M, Hernandez MT, Gonzalez-Calle V, Cedena MT, Paiva B, San-Miguel JF, Lahuerta JJ, Mateos MV, Martinez-Lopez J, Orfao A, Gonzalez M, Garcia-Sanz R. Medina A, et al. Among authors: cedena mt. Blood Cancer J. 2020 Oct 30;10(10):108. doi: 10.1038/s41408-020-00377-0. Blood Cancer J. 2020. PMID: 33127891 Free PMC article. Clinical Trial.
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. Martinez-Lopez J, et al. Among authors: cedena mt. J Hematol Oncol. 2021 Aug 17;14(1):126. doi: 10.1186/s13045-021-01135-w. J Hematol Oncol. 2021. PMID: 34404440 Free PMC article.
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.
Puig N, Flores-Montero J, Burgos L, Cedena MT, Cordón L, Pérez JJ, Sanoja-Flores L, Manrique I, Rodríguez-Otero P, Rosiñol L, Martínez-López J, Mateos MV, Lahuerta JJ, Bladé J, San Miguel JF, Orfao A, Paiva B. Puig N, et al. Among authors: cedena mt. Cancers (Basel). 2021 Sep 30;13(19):4924. doi: 10.3390/cancers13194924. Cancers (Basel). 2021. PMID: 34638406 Free PMC article.
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig N, Contreras MT, Agulló C, Martínez-López J, Oriol A, Blanchard MJ, Ríos R, Martín J, Iñigo MB, Sureda A, Hernández MT, de la Rubia J, González-Calle V, Krsnik I, Cabañas V, Palomera L, Moraleda JM, Bargay J, Cedena MT, Paiva B, Rosiñol L, Bladé J, San Miguel J, Lahuerta JJ, Mateos MV. Puig N, et al. Among authors: cedena mt. Blood Adv. 2022 Jun 14;6(11):3234-3239. doi: 10.1182/bloodadvances.2021006762. Blood Adv. 2022. PMID: 35157768 Free PMC article. Clinical Trial.
Impact of IPSS-M implementation in real-life clinical practice.
Zamanillo I, Poza M, Ayala R, Rapado I, Martinez-Lopez J, Cedena MT. Zamanillo I, et al. Among authors: cedena mt. Front Oncol. 2023 May 18;13:1199023. doi: 10.3389/fonc.2023.1199023. eCollection 2023. Front Oncol. 2023. PMID: 37274292 Free PMC article.
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A, Martín-Muñoz A, Poza M, Dorado S, García-Ortiz A, Revilla E, Sarandeses P, Ruiz-Heredia Y, Baumann T, Rodríguez A, Calbacho M, Sánchez PM, Pina JMS, García-Sancho AM, Figaredo G, Rufián L, Rodríguez M, Carneros L, Martínez-Laperche C, Bastos-Oreiro M, Wang C, Cedena MT, Rapado I, de Toledo P, Gallardo M, Valeri A, Ayala R, Martínez-López J, Barrio S. Jiménez-Ubieto A, et al. Among authors: cedena mt. Front Immunol. 2023 Jun 5;14:1188818. doi: 10.3389/fimmu.2023.1188818. eCollection 2023. Front Immunol. 2023. PMID: 37342332 Free PMC article.
60 results